New Cigna Study Shows Integrated Medical, Pharmacy and Behavioral Benefit Design Delivers Better Health Outcomes and Improves Affordability
- Annual cost savings greater than $6,700 for patients with an oncology diagnosis.
- Connecting physical and mental health delivers better engagement, outcomes, and lowers costs.
News provided by
Share this article
Share this article
BLOOMFIELD, Conn., Jan. 12, 2021 /PRNewswire/ Taking a whole-person approach to health by integrating Cigna medical, pharmacy and behavioral benefits drives better health engagement, outcomes and lowers total health care costs, according to Cigna s fifth annual
Value of Integration study, released today. This year s findings are based on a two-year analysis of more than 2.2 million customer medical claims from Cigna customers who receive coverage through their employer.
MedC Biopharma and Sana Healthcare Partner to Advance Skin Oncology Platform
News provided by
Share this article
Share this article
TORONTO, Jan. 12, 2021 /PRNewswire/ MedC Biopharma Corporation ( MedC ), a Canadian clinical-stage biopharmaceutical company that develops and commercializes products containing cannabinoids and/or other natural compounds, is pleased to announce a strategic partnership agreement with Sana Healthcare ( Sana ). Sana is a specialist importer, wholesaler and distributor of cannabis-based medicines and supports biopharmaceutical companies in selecting and then pursuing the most appropriate clinic pathways in the UK. The partnership will advance the development of MedC s product platform for the treatment of Cutaneous T-Cell Lymphoma (CTCL) Sezary Syndrome.
JUD care Obtains FDA Approval for Its Portable Ward sRoom
USA - English
Share this article
Share this article
SHENZHEN,China, Jan. 12, 2021 /PRNewswire/ JUD care, a leading high-tech enterprise in the field of smart medical and healthcare solutions, has obtained approval from the US Food and Drug Administration (FDA) for the portable ward sRoom ( sRoom ), a revolutionary solution for patient isolation that enables hospitals to quickly set up emergency isolation rooms.
JUD care, a leading high-tech enterprise in the field of smart medical and healthcare solutions, has obtained approval from the US Food and Drug Administration (FDA) for the portable ward sRoom, a revolutionary solution for patient isolation that enables hospitals to quickly set up emergency isolation rooms.
Share this article
Share this article
LISBON, Portugal, Jan. 12, 2021 /PRNewswire/ Hovione, the leader in Pharmaceutical Spray Drying, today announced the launch of ASD-HIPROS, a proprietary screening service for spray dried dispersions. This platform is the most advanced and most accurate tool to identify optimal and commercially viable Amorphous Solid Dispersions formulation by Spray Drying (ASDs). During drug development, it is crucial to quickly find the optimal formulation assuring fast progress to clinical supplies and minimal formulation changes till commercialization.
ASD-HIPROS, the Hovione Intelligent PROprietary Screening methodology, is able to rapidly screen for the best combination of polymers, drug loads, surfactants and solvents by using an advanced computational tool followed by producing scale-independent representative samples of the most promising formulations, which are evaluated for performance and stability.
Share this article
MISGAV, Israel, Jan. 12, 2021 /PRNewswire/
Biond Biologics Ltd. ( Biond or the Company ), a privately-held biopharmaceutical company, developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, today announced that it has entered into an exclusive worldwide license agreement with Sanofi (EURONEXT: SAN) (NASDAQ: SNY), for the development and commercialization of BND-22.
BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors. ILT2, a member of the ILT family of immuno-modulating receptors, is an inhibitory receptor expressed on both innate and adaptive immune cells that binds MHC class I molecules including HLA-G, an immunosuppressive protein expressed by multiple tumor types.